MAVORIC
MAVORIC showed that mogamulizumab, an antibody that clears the malignant T cells that carry the CCR4 protein, kept cutaneous T-cell lymphoma under control for longer than the standard tablet vorinostat, and did especially well in the blood-involved Sezary form, which led to its approval.
Overview
MAVORIC was an open-label phase 3 trial in patients with mycosis fungoides or Sezary syndrome who had failed at least one systemic therapy. Patients were randomised to mogamulizumab, an afucosylated antibody against CCR4 that depletes malignant T cells, or to vorinostat, an approved histone deacetylase inhibitor; patients progressing on vorinostat could cross over.
Mogamulizumab significantly prolonged progression-free survival, the primary endpoint, with higher response rates, and the benefit was greatest in patients with blood involvement, the hallmark of Sezary syndrome. It was the first randomised trial in cutaneous T-cell lymphoma to compare two systemic drugs head to head and led to approval of mogamulizumab in the United States in August 2018.
Similar pages
not linked directly; found by shared links- TrialALCANZA
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag subtype-trials.
- TrialECHELON-2
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag subtype-trials.
- TargetCCR4
Shares Kyowa Kirin, Mogamulizumab, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TreatmentRomidepsin
Shares Vorinostat, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TreatmentMethoxsalen (extracorporeal photopheresis)
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TreatmentBexarotene
Shares Vorinostat, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
- TechnologyTotal skin electron beam therapy
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TrialA Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).